About Akorn (NASDAQ:AKRX)
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:AKRX
CUSIP00972810
Phone847-279-6100
Debt
Debt-to-Equity Ratio0.98%
Current Ratio4.27%
Quick Ratio3.19%
Price-To-Earnings
Trailing P/E Ratio6.24
Forward P/E RatioInfinity
P/E Growth1.05
Sales & Book Value
Annual Sales$841.04 million
Price / Sales2.02
Cash Flow$0.5458 per share
Price / Cash24.79
Book Value$6.65 per share
Price / Book2.03
Profitability
EPS (Most Recent Fiscal Year)$2.17
Net Income$-24,550,000.00
Net Margins-2.92%
Return on Equity-0.43%
Return on Assets-0.19%
Miscellaneous
Employees2,308
Outstanding Shares125,260,000
Akorn (NASDAQ:AKRX) Frequently Asked Questions
What is Akorn's stock symbol?
Akorn trades on the NASDAQ under the ticker symbol "AKRX."
How were Akorn's earnings last quarter?
Akorn (NASDAQ:AKRX) posted its quarterly earnings results on Thursday, August, 4th. The company reported $0.58 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.55 by $0.03. The company earned $280.70 million during the quarter, compared to the consensus estimate of $272.99 million. Akorn had a negative return on equity of 0.43% and a negative net margin of 2.92%. Akorn's revenue for the quarter was up 27.1% compared to the same quarter last year. View Akorn's Earnings History.
What price target have analysts set for AKRX?
7 analysts have issued 1-year target prices for Akorn's stock. Their predictions range from $14.00 to $34.00. On average, they anticipate Akorn's share price to reach $28.20 in the next year. View Analyst Ratings for Akorn.
Are investors shorting Akorn?
Akorn saw a decline in short interest in the month of March. As of March 15th, there was short interest totalling 10,952,583 shares, a decline of 47.3% from the February 28th total of 20,769,706 shares. Based on an average daily trading volume, of 2,156,507 shares, the short-interest ratio is currently 5.1 days. Approximately 11.8% of the shares of the company are sold short.
Who are some of Akorn's key competitors?
Some companies that are related to Akorn include Ionis Pharmaceuticals (IONS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Agios Pharmaceuticals (AGIO), Galápagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP) and Ligand Pharmaceuticals (LGND).
Who are Akorn's key executives?
Akorn's management team includes the folowing people:
- Mr. Rajat Rai, Chief Exec. Officer (Age 51)
- Mr. Duane A. Portwood, Exec. VP & CFO (Age 52)
- Dr. Bruce Kutinsky, Chief Operating Officer (Age 52)
- Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 53)
- Mr. Jonathan Kafer, Exec. VP of Sales & Marketing (Age 55)
Has Akorn been receiving favorable news coverage?
Media coverage about AKRX stock has been trending somewhat positive this week, Accern reports. The research firm scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akorn earned a news sentiment score of 0.13 on Accern's scale. They also gave news stories about the company an impact score of 45.98 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Akorn's major shareholders?
Akorn's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include
FMR LLC
(9.29%) and
FMR LLC
(9.29%). Company insiders that own Akorn stock include Alan D Weinstein, Brian Tambi, Bruce Kutinsky, John N Kapoor, Joseph Bonaccorsi, Kenneth Abramowitz and Ronald M Johnson. View Institutional Ownership Trends for Akorn.
How do I buy shares of Akorn?
Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akorn's stock price today?
One share of AKRX stock can currently be purchased for approximately $13.53.
How big of a company is Akorn?
Akorn has a market capitalization of $1.63 billion and generates $841.04 million in revenue each year. The company earns $-24,550,000.00 in net income (profit) each year or $2.17 on an earnings per share basis. Akorn employs 2,308 workers across the globe.
How can I contact Akorn?
Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]
MarketBeat Community Rating for Akorn (AKRX)
MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Akorn (NASDAQ:AKRX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Akorn in the last 12 months. Their average twelve-month price target is $28.20, suggesting that the stock has a possible upside of 108.43%. The high price target for AKRX is $34.00 and the low price target for AKRX is $14.00. There are currently 7 hold ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 1.91 |
| Ratings Breakdown: | 0 Sell Rating(s)
7 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
7 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $28.20 | $34.00 | $30.20 | $29.1250 |
| Price Target Upside: | 108.43% upside | 84.68% upside | 7.13% downside | 12.48% downside |
Akorn (NASDAQ:AKRX) Consensus Price Target History
Akorn (NASDAQ:AKRX) Analyst Ratings History
Show:
(Data available from 4/25/2016 forward)
Akorn (NASDAQ:AKRX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Akorn (NASDAQ AKRX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 28.20%
Institutional Ownership Percentage: 78.08%
Akorn (NASDAQ AKRX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/25/2018 | John N. Kapoor | Major Shareholder | Sell | 13,629 | $32.67 | $445,259.43 | |  |
| 11/21/2017 | Brian Tambi | Director | Sell | 15,100 | $33.35 | $503,585.00 | | |
| 8/4/2017 | Brian Tambi | Director | Sell | 5,165 | $33.37 | $172,356.05 | | |
| 8/3/2017 | Bruce Kutinsky | COO | Sell | 40,000 | $33.46 | $1,338,400.00 | 317,480 | |
| 8/15/2016 | Kenneth Abramowitz | Director | Sell | 2,691 | $30.44 | $81,914.04 | 20,786 | |
| 6/14/2016 | Joseph Bonaccorsi | SVP | Sell | 6,500 | $29.84 | $193,960.00 | 449,112 | |
| 6/10/2016 | Kenneth Abramowitz | Director | Sell | 14,675 | $30.16 | $442,598.00 | 33,185 | |
| 6/9/2016 | Bruce Kutinsky | COO | Sell | 142,000 | $31.12 | $4,419,040.00 | 58,695 | |
| 6/7/2016 | Ronald M Johnson | Director | Sell | 7,542 | $31.49 | $237,497.58 | 111,807 | |
| 6/6/2016 | Kenneth Abramowitz | Director | Sell | 10,900 | $31.37 | $341,933.00 | 16,985 | |
| 6/3/2016 | Joseph Bonaccorsi | SVP | Sell | 90,250 | $31.23 | $2,818,507.50 | 470,862 | |
| 6/2/2016 | Alan D Weinstein | Director | Sell | 50,000 | $30.93 | $1,546,500.00 | 83,857 | |
| 4/21/2015 | Mark M Silverberg | VP | Sell | 29,000 | $55.00 | $1,595,000.00 | | |
| 3/10/2015 | John N Kapoor | Director | Buy | 19,000 | $44.26 | $840,940.00 | | |
| 3/3/2015 | Rajat Rai | CEO | Buy | 5,000 | $47.70 | $238,500.00 | | |
| 2/18/2015 | Joseph Bonaccorsi | Insider | Sell | 40,827 | $47.33 | $1,932,341.91 | | |
| 2/10/2015 | Ronald M Johnson | Director | Sell | 17,173 | $46.44 | $797,514.12 | | |
| 1/26/2015 | Rajat Rai | CEO | Sell | 873,985 | $41.89 | $36,611,231.65 | | |
| 1/12/2015 | Mark M Silverberg | VP | Sell | 38,602 | $41.00 | $1,582,682.00 | | |
| 1/9/2015 | Ronald M Johnson | Director | Sell | 17,173 | $40.46 | $694,819.58 | | |
| 1/2/2015 | Ronald M Johnson | Director | Sell | 14,300 | $36.12 | $516,516.00 | | |
| 1/2/2015 | Timothy A Dick | CFO | Sell | 30,150 | $36.03 | $1,086,304.50 | | |
| 12/15/2014 | Brian Tambi | Director | Sell | 1,200 | $41.86 | $50,232.00 | | |
| 12/12/2014 | Adrienne L Graves | Director | Sell | 9,557 | $41.09 | $392,697.13 | | |
| 12/11/2014 | John N Kapoor | Director | Sell | 50,000 | $41.19 | $2,059,500.00 | | |
| 12/9/2014 | John R Sabat | VP | Sell | 43,173 | $40.53 | $1,749,801.69 | | |
| 12/1/2014 | Timothy A Dick | CFO | Sell | 30,875 | $39.23 | $1,211,226.25 | | |
| 11/3/2014 | Timothy A Dick | CFO | Sell | 122,222 | $44.08 | $5,387,545.76 | | |
| 10/1/2014 | Timothy A Dick | CFO | Sell | 122,222 | $35.24 | $4,307,103.28 | | |
| 9/12/2014 | Brian Tambi | Director | Sell | 13,800 | $38.00 | $524,400.00 | | |
| 9/11/2014 | Joseph Bonaccorsi | Insider | Sell | 116,800 | $37.89 | $4,425,552.00 | | |
| 9/8/2014 | Kenneth Abramowitz | Director | Sell | 4,500 | $36.54 | $164,430.00 | | |
| 9/8/2014 | Rajat Rai | CEO | Sell | 147,000 | $36.78 | $5,406,660.00 | | |
| 9/8/2014 | Timothy A Dick | CFO | Sell | 45,000 | $37.61 | $1,692,450.00 | | |
| 9/4/2014 | Alan D Weinstein | Director | Sell | 5,000 | $38.49 | $192,450.00 | | |
| 8/26/2014 | John N Kapoor | Director | Sell | 50,000 | $38.99 | $1,949,500.00 | | |
| 8/7/2014 | Rajat Rai | CEO | Sell | 903,659 | $33.62 | $30,381,015.58 | | |
| 6/13/2014 | Brian Tambi | Director | Buy | 1,000 | $27.62 | $27,620.00 | | |
| 5/16/2014 | Rajat Rai | CEO | Buy | 5,000 | $26.76 | $133,800.00 | 31,271 | |
| 5/14/2014 | Kenneth Abramowitz | Director | Sell | 2,557 | $26.79 | $68,502.03 | 4,300 | |
| 12/9/2013 | Alan Weinstein | Director | Sell | 20,000 | $25.52 | $510,400.00 | 53,857 | |
| 12/3/2013 | Kenneth Abramowitz | Director | Sell | 5,000 | $25.35 | $126,750.00 | 21,057 | |
| 12/12/2012 | Alan D Weinstein | Director | Buy | 30,500 | $13.67 | $416,935.00 | | |
(Data available from 1/1/2013 forward)
Akorn (NASDAQ AKRX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Akorn Target of Unusually Large Options Trading (AKRX)
www.americanbankingnews.com - April 25 at 8:12 AM |
 | AKORN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class ...
globenewswire.com - April 24 at 4:46 PM |
 | EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 – AKRX
finance.yahoo.com - April 24 at 4:46 PM |
 | Fresenius Abandons $4.3 Billion Takeover Bid
www.bloomberg.com - April 23 at 4:31 PM |
 | Is the Options Market Predicting a Spike in Akorn (AKRX) Stock? April 23, 2018
www.zacks.com - April 23 at 4:31 PM |
| 3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 23 at 4:31 PM |
| Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%
finance.yahoo.com - April 23 at 4:31 PM |
| Akorn Shares Crash After Fresenius Walks Away From Merger Deal
finance.yahoo.com - April 23 at 4:31 PM |
| Piper Jaffray Reiterates Hold Rating for Akorn (AKRX)
www.americanbankingnews.com - April 23 at 9:48 AM |
| Craig Hallum Reiterates "Hold" Rating for Akorn (AKRX)
www.americanbankingnews.com - April 23 at 9:18 AM |
 | BRIEF-Akorn Asks Delaware Court To Require Fresenius Kabi To Fulfill Its Obligations Under Merger Agreement
www.reuters.com - April 23 at 9:04 AM |
| Fresenius shares gain after it ditches Akorn takeover
finance.yahoo.com - April 23 at 9:04 AM |
| Akorn's Stock Crashes as Germany's Fresenius Ends Takeover Amid Data Allegations
finance.yahoo.com - April 23 at 9:04 AM |
| Germany's Fresenius, US-based Akorn at odds over merger deal
finance.yahoo.com - April 23 at 9:04 AM |
| Akorn files complaint against Fresenius for ending merger deal
finance.yahoo.com - April 23 at 9:04 AM |
| Akorn Asks Delaware Court to Require Fresenius Kabi to Fulfill Its Obligations under Merger Agreement
finance.yahoo.com - April 23 at 9:04 AM |
| Akorn's stock plunged toward 5-year low after Fresenius terminates merger deal
finance.yahoo.com - April 23 at 9:04 AM |
| Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know
finance.yahoo.com - April 23 at 9:04 AM |
 | Germany's Fresenius, US-based Akorn at odds over merger deal
marketbeat.com - April 23 at 6:12 AM |
| BRIEF-Akorn Issues Statement In Response To Fresenius Seeking To Terminate Merger
www.reuters.com - April 22 at 5:26 PM |
| Fresenius Terminates $4.3 Billion Takeover of Akorn After Probe
www.bloomberg.com - April 22 at 5:26 PM |
 | AKRX INVESTOR ALERT: Rosen Law Firm Reminds Akorn, Inc. Investors of Important May 7 Deadline in Class Action ...
www.businesswire.com - April 21 at 9:12 AM |
| AKRX INVESTOR ALERT: Rosen Law Firm Reminds Akorn, Inc. Investors of Important May 7 Deadline in Class Action – AKRX
finance.yahoo.com - April 21 at 9:12 AM |
| Akorn (AKRX) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM |
| AKRX ALERT: Important May 7, 2018 Lead Plaintiff Deadline in Class Action - AKRX
finance.yahoo.com - April 20 at 4:35 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX
finance.yahoo.com - April 20 at 4:35 PM |
| Akorn (AKRX) PT Set at $34.00 by Royal Bank of Canada
www.americanbankingnews.com - April 20 at 3:02 PM |
| Akorn (AKRX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 19 at 1:34 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 – AKRX
finance.yahoo.com - April 18 at 4:49 PM |
| Akorn (AKRX) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 17 at 12:04 AM |
| Akorn (AKRX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 16 at 7:00 PM |
| The Klein Law Firm Notifies Investors of a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (AKRX)
finance.yahoo.com - April 16 at 4:30 PM |
| SHAREHOLDER DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 16 at 4:30 PM |
| Akorn (AKRX) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 14 at 6:54 PM |
| Akorn (AKRX) Lowered to C at TheStreet
www.americanbankingnews.com - April 13 at 8:18 PM |
| SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Akorn, Inc. (AKRX) & Lead Plaintiff Deadline: May 7, 2018
finance.yahoo.com - April 13 at 4:34 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 7, 2018 - AKRX
finance.yahoo.com - April 13 at 4:34 PM |
| Akorn (AKRX) Downgraded by BidaskClub
www.americanbankingnews.com - April 13 at 11:01 AM |
| Deutsche Bank Reiterates Hold Rating for Akorn (AKRX)
www.americanbankingnews.com - April 12 at 11:07 AM |
| DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Akorn, Inc. to Contact the Firm
finance.yahoo.com - April 12 at 10:12 AM |
 | AKORN ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Akorn, Inc. - AKRX
www.prnewswire.com - April 11 at 7:28 PM |
| Akorn, Inc. Alert: Important May 7, 2018 Lead Plaintiff Deadline in Class Action- AKRX
finance.yahoo.com - April 11 at 4:34 PM |
| Piper Jaffray Analysts Give Akorn (AKRX) a $34.00 Price Target
www.americanbankingnews.com - April 9 at 8:06 PM |
| AKRX EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Akorn, Inc. and ...
www.businesswire.com - April 9 at 4:30 PM |
| AKRX EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Akorn, Inc. and a Lead Plaintiff Deadline of May 7, 2018
finance.yahoo.com - April 9 at 4:30 PM |
| IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Securities Class Action Lawsuit Against Akorn, Inc. and Reminds Investors With Losses In Excess of $50,000 to Contact The Firm
finance.yahoo.com - April 9 at 4:30 PM |
| Akorn (AKRX) Given "Hold" Rating at Royal Bank of Canada
www.americanbankingnews.com - April 8 at 11:01 AM |
| Akorn (AKRX) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - April 5 at 2:08 PM |
| EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Akorn, Inc. of a Class Action Lawsuit and a Lead ...
www.businesswire.com - April 4 at 4:56 PM |
| The Klein Law Firm Announces Commencement of a Class Action Filed on Behalf of Akorn, Inc. Shareholders and a Lead Plaintiff Deadline of May 7, 2018 (AKRX)
finance.yahoo.com - April 4 at 4:56 PM |
Akorn (NASDAQ:AKRX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Akorn (NASDAQ:AKRX) Income Statement, Balance Sheet and Cash Flow Statement
Akorn (NASDAQ AKRX) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
